Affordable Access

deepdyve-link
Publisher Website

Risk factors for exacerbations of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis.

Authors
  • Nagaoki, Yuko1
  • Aikata, Hiroshi1, 2
  • Daijyo, Kana1
  • Teraoka, Yuji1
  • Honda, Fumi1
  • Nakamura, Yuki1
  • Hatooka, Masahiro1
  • Morio, Kei1
  • Fujino, Hatsue1, 2
  • Nakahara, Takashi1, 2
  • Kawaoka, Tomokazu1, 2
  • Miki, Daiki2, 3
  • Tsuge, Masataka1, 2, 4
  • Hiramatsu, Akira1, 2
  • Imamura, Michio1, 2
  • Kawakami, Yoshiiku1, 2
  • Ochi, Hidenori1, 2, 3
  • Chayama, Kazuaki1, 2, 3
  • 1 Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan. , (Japan)
  • 2 Liver Research Project Center, Hiroshima University, Hiroshima, Japan. , (Japan)
  • 3 Laboratory for Digestive Diseases, RIKEN Center for Integrative Medical Sciences, Hiroshima, Japan. , (Japan)
  • 4 Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan. , (Japan)
Type
Published Article
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
Publication Date
Nov 08, 2017
Identifiers
DOI: 10.1111/hepr.12996
PMID: 29114970
Source
Medline
Keywords
License
Unknown

Abstract

The presence of portosystemic collateral vessels at start of NAs treatment increases the risk of GEVs worsening and development portosystemic encephalopathy in patients with HBV-related cirrhosis despite of improvement of liver function and successful in reducing viral loads with NAs treatment.

Report this publication

Statistics

Seen <100 times